Sanofi India Faces Rs 23.74 Crore GST Show-Cause Notice

Sanofi India Confronts Rs 23.74 Crore GST Show-Cause Notice Amid Financial Growth

The pharmaceutical giant faces scrutiny over alleged excess tax claims, but reassures investors of its financial stability.

Details of the Show-Cause Notice

Sanofi India has been issued a show-cause notice by the Commercial Tax Officer (Audit)-6.1, DGSTO-6, Bengaluru, alleging that the company claimed excess input tax credit for the financial year 2022-23. The notice, dated September 25, 2026, cites a proposed tax liability of Rs 14.43 crore along with interest amounting to Rs 9.31 crore, culminating in a total liability of Rs 23.74 crore.

In response, Sanofi India stated that it is currently examining the notice in consultation with its tax advisors and plans to submit a formal response within the stipulated timeframe. The company has expressed confidence that the notice will not adversely affect its financial performance, operations, or ongoing activities.

Financial Performance Amid Regulatory Scrutiny

Despite the regulatory challenges, Sanofi India has demonstrated robust financial performance. For the second quarter ending June 2026, the company reported a net profit of Rs 83.50 crore, reflecting a 20.14% increase compared to the same quarter in the previous year. Additionally, net sales rose by 7.73% to reach Rs 437.70 crore, indicating a positive growth trajectory.

This growth in profitability and sales underscores the company’s resilience and operational efficiency, even as it navigates through the complexities of tax compliance and regulatory oversight.

Market Reaction and Investor Sentiment

On the day the notice was issued, Sanofi India’s shares experienced a slight uptick, rising by 0.34% to close at Rs 3,143.40. This modest increase suggests that investors remain optimistic about the company’s fundamentals and its ability to manage regulatory challenges effectively.

The market’s reaction may also reflect confidence in Sanofi India’s established reputation in the pharmaceutical sector, as well as its proactive approach to addressing the GST notice.

Key Highlights

• Sanofi India received a Rs 23.74 crore GST show-cause notice from Karnataka authorities.
• The notice alleges excess input tax credit claims for FY2022-23.
• The company reported a 20.14% rise in net profit for Q2 June 2026.
• Shares of Sanofi India rose 0.34% on the day of the notice.
• Sanofi India reassures investors of no adverse impact on its operations.

Investor Note: The ongoing scrutiny from GST authorities presents a challenge for Sanofi India, but the company’s strong financial performance and proactive management may mitigate potential risks. Investors should monitor the situation closely while considering the company’s overall growth trajectory.